Pemigatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pemigatinib
Accession Number
DB15102
Type
Small Molecule
Groups
Investigational
Description

Pemigatinib is under investigation in clinical trial NCT03656536 (A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)).

Structure
Thumb
Synonyms
  • INCB054828
Categories
Not Available
UNII
Y6BX7BL23K
CAS number
1513857-77-6
Weight
Average: 487.508
Monoisotopic: 487.203110695
Chemical Formula
C24H27F2N5O4
InChI Key
HCDMJFOHIXMBOV-UHFFFAOYSA-N
InChI
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
IUPAC Name
11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.0^{2,6}]trideca-1,3,6,8-tetraen-12-one
SMILES
CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
68007304
BindingDB
301310

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentAdvanced Cholangiocarcinoma / FGFR1 Gene Alteration Positive / FGFR2 Gene Alteration Positive / FGFR3 Gene Alteration Positive / IDH1 Gene Mutation / IDH1 NP_005887.2:p.R132C / IDH1 NP_005887.2:p.R132G / IDH1 NP_005887.2:p.R132H / IDH1 NP_005887.2:p.R132L / IDH1 NP_005887.2:p.R132S / Metastatic Cholangiocarcinoma / Unresectable Cholangiocarcinoma1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentSolid Tumors and Hematologic Malignancy / Tumors, Solid1
1, 2RecruitingTreatmentBreast Cancer / Cholangiocarcinomas / Endometrial Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Malignant Neoplasm of Stomach / Malignant Solid Tumours / MPN / MPN (Myeloproliferative Neoplasms) / Multiple Myeloma (MM) / Myeloproliferative Neoplasms / Neoplasms, Endometrial / NSCLC (Non-small Cell Lung Carcinoma) / Solid Tumors and Hematologic Malignancy / Stomach Neoplasms / Transitional Cell Carcinoma / Tumors, Solid / UC / UC (Urothelial Cancer) / Urothelial Cancer1
2Active Not RecruitingTreatmentCholangiocarcinomas1
2Not Yet RecruitingTreatmentCholangiocarcinomas1
2Not Yet RecruitingTreatmentFGFR1 Gene Amplification / FGFR1 Gene Mutation / FGFR1 Gene Translocation / FGFR2 Gene Amplification / FGFR2 Gene Mutation / FGFR2 Gene Translocation / FGFR3 Gene Amplification / FGFR3 Gene Mutation / FGFR3 Gene Translocation / Metastatic Colorectal Carcinoma / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Unresectable Colorectal Carcinoma1
2Not Yet RecruitingTreatmentUrothelial Cancer1
2RecruitingTreatmentAdvanced or Metastatic Solid Tumors / FGFR Mutations / FGFR Translocations1
2RecruitingTreatmentCancer, Bladder / NMIBC / Non-muscle Invasive Bladder Cancer (NMIBC) / Urothelial Carcinoma Recurrent1
2RecruitingTreatmentMPN (Myeloproliferative Neoplasms) / Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement1
2RecruitingTreatmentSolid Tumor Malignancies1
2RecruitingTreatmentTransitional Cell Carcinoma / UC (Urothelial Cancer)1
2RecruitingTreatmentUnresectable Urothelial Carcinoma / Urothelial carcinoma ureter metastatic1
3RecruitingTreatmentMetastatic Cholangiocarcinoma / Unresectable Cholangiocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.144 mg/mLALOGPS
logP2.26ALOGPS
logP1.82ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.88ChemAxon
pKa (Strongest Basic)5.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.16 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity125.32 m3·mol-1ChemAxon
Polarizability49.93 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:50 / Updated on March 01, 2020 22:01

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates